Manual Placenta Removal and Umbilical Cord Oxytocin Injection for Postpartum Hemorrhage Management in Nigeria: A Narrative Review of Evidence from 2020 to 2026

References

[1] World Health Organization, “WHO recommendation on umbilical vein injection of oxytocin for the treatment of retained placenta,” World Health Organization, 2020. WHO

[2] World Health Organization, “Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage,” World Health Organization, 2023.

[3] I. D. Gallos, A. J. Devall, and J. Martin, “Randomized trial of early detection and treatment of postpartum hemorrhage (E-MOTIVE),” The New England Journal of Medicine, vol. 389, no. 1, pp. 22–33, 2023.

[4] Global Burden of Disease PPH Collaborators, “Global burden, disparities, and determinants of postpartum haemorrhage among women who gave birth: An umbrella review of systematic reviews,” BMC Medicine, vol. 19, no. 1, Art. no. 254, 2021.

[5] Causes of Maternal Mortality Collaboration, “Causes of maternal mortality in sub-Saharan Africa: A systematic review of studies published from 2015 to 2020,” Journal of Global Health, vol. 11, Art. no. 04052, 2021.

[6] Federal Ministry of Health, “National reproductive, maternal, newborn, child, adolescent, elderly health plus nutrition (RMNCAEH+N) quality of care monitoring report,” Federal Ministry of Health, Abuja, Nigeria, 2021.

[7] Federal Ministry of Health, “National guideline for the management of postpartum haemorrhage,” Federal Ministry of Health and Social Welfare, Abuja, Nigeria, 2023.

[8] SEMA Nigeria, “Sustainable market alignment for reproductive health supplies in Nigeria: Assessment and recommendations preview,” PSHAN Publications, 2022.

[9] A. A. Adegoke, F. E. Okonofua, and O. M. Campbell, “Predictors of primary postpartum haemorrhage in a tertiary teaching hospital in Ekiti State, Nigeria: A facility-based analytical study,” Nigerian Journal of Clinical Practice, vol. 24, no. 5, pp. 712–720, 2021.

[10] J. O. Egede, R. C. Onoh, and O. U. Umeora, “An appraisal of retained placenta as a complication of third stage of labour at Alex Ekwueme Federal University Teaching Hospital, Abakaliki,” Research Journal of Medical Sciences, vol. 15, no. 2, pp. 88–96, 2021.

[11] B. A. Olofinbiyi, B. N. Olagbuji, and I. P. Ade-Ojo, “A 4-year audit of retained placenta at Ekiti State University Teaching Hospital, South Western Nigeria,” Global Public Health Journal, vol. 6, no. 2, pp. 45–53, 2021.

[12] National Institute for Health and Care Excellence, “Intrapartum care for healthy women and babies (NICE Guideline NG235),” National Institute for Health and Care Excellence, 2023.

[13] Royal College of Physicians of Ireland, “National clinical practice guideline: Intrapartum care for women on the supported care pathway (Guideline No. 42),” RCPI Clinical Advisory Group, 2021.

[14] T. A. Lawrie, O. T. Oladapo, and A. M. Gulmezoglu, “Detection and management of postpartum haemorrhage: Qualitative evidence on healthcare providers' knowledge and practices in Kenya, Nigeria, and South Africa,” BMC Health Services Research, vol. 22, no. 1, Art. no. 340, 2022.

[15] O. T. Oladapo, J. P. Souza, and A. M. Gulmezoglu, “Assessment of diagnostic accuracy and adherence to maternal and child health guidelines as a measure of clinical competence of frontline healthcare workers in Nigeria,” PLOS ONE, vol. 15, no. 8, Art. no. e0237120, 2020.

[16] R. Mori, J. M. Nardin, and R. Yamamoto, “Umbilical vein injection for management of retained placenta,” Cochrane Database of Systematic Reviews, 2021(4), CD001337, 2021.

[17] J. M. Nardin, A. Weeks, and G. Carroli, “Umbilical vein injection after childbirth for management of retained placenta: A systematic review,” World Health Organization Database, WHO/RHR/20.04, 2020.

[18] Ebonyi State Ministry of Health, “Health sector strategic blueprint: Maternal and perinatal mortality reduction plan,” Ebonyi State Government Press, 2022.

[19] C. Anyakora, W. O. Erhun, and A. Bankole, “Modelling the economic impact of substandard uterotonics on postpartum haemorrhage in Nigeria: Safeguarding medicine quality can reduce costs and contribute towards universal health coverage,” BMJ Public Health, vol. 2, no. 1, Art. no. e000142, 2021.

[20] A. Bankole, C. Anyakora, and K. Torpey, “A descriptive study of healthcare providers' experiences with the use and quality of oxytocin for the prevention of postpartum hemorrhage in Nigeria: A nation-wide survey,” PLOS ONE, vol. 17, no. 4, Art. no. e0266120, 2022.

[21] L. O. Omo-Aghahowa, F. E. Okonofua, and J. A. Unuigbe, “Ten-year review of burden and outcomes of retained placenta following vaginal delivery at Delta State University Teaching Hospital, Nigeria,” Tropical Journal of Obstetrics and Gynaecology, vol. 37, no. 1, pp. 22–29, 2020.

[22] F. Althabe, I. D. Gallos, and G. J. Hofmeyr, “Early detection and a treatment bundle strategy for postpartum haemorrhage: Findings from the E-MOTIVE trial,” The New England Journal of Medicine, vol. 389, no. 1, pp. 11–21, 2023.

[23] G. J. Hofmeyr, Z. Qureshi, and F. Althabe, “Clinical care processes for early postpartum haemorrhage diagnosis: A nested observational study within the E-MOTIVE trial,” Frontiers in Global Women's Health, vol. 4, Art. no. 112045, 2023.

[24] O. O. Lawal, N. A. Adeleke, and O. B. Fasubaa, “Assessment of knowledge and practice on prevention of postpartum hemorrhage among skilled birth providers in primary health care facilities in Osogbo, Osun State,” Adeleke University Journal of Science, vol. 3, no. 1, pp. 112–124, 2022.

[25] Z. Babandi, S. Abubakar, and M. Umar, “Availability and utilization of Basic Emergency Obstetric and Newborn Care services in Jigawa State, Northwest Nigeria,” Journal of Community Medicine and Primary Health Care, vol. 33, no. 2, pp. 45–58, 2021.

[26] F. E. Okonofua, L. F. Ntoimo, and R. N. Ogu, “Improving maternal health outcomes through skilled birth attendance in hard-to-reach communities of Adamawa State, Nigeria,” International Journal of Women's Health, vol. 13, pp. 891–902, 2021.

[27] S. M. Ishaku, E. A. Udofia, and E. T. Agida, “Placenta accreta spectrum in unscarred uterus: A case series in a tertiary facility in Northern Nigeria,” East African Medical Journal, vol. 99, no. 4, pp. 1420–1428, 2022.

[28] E. A. Udofia, S. M. Ishaku, and E. T. Agida, “Demographic pattern and perioperative challenges in patients with placenta accreta spectrum in a Nigerian tertiary facility,” Journal of South Asian Federation of Obstetrics and Gynaecology, vol. 13, no. 2, pp. 94–99, 2021.

[29] G. A. Pipingas, G. J. Hofmeyr, and R. Solomons, “Umbilical vein oxytocin for the treatment of retained placenta: A double-blind randomized controlled trial,” British Journal of Obstetrics and Gynaecology, vol. 100, no. 6, pp. 585–590, 1993.

[30] Frontiers Meta-Analysis Group, “Side-effects of intravenously versus intramuscularly oxytocin for postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials,” Frontiers in Global Women's Health, vol. 3, Art. no. 891204, 2022.

[31] Comparative Study Group, “Comparative study between use of intraumbilical oxytocin and conventional intravenous oxytocin for the management of third stage of labour,” Indian Journal of Obstetrics and Gynecology Research, vol. 8, no. 3, pp. 312–318, 2021.

[32] Original Article Group, “Comparison of the mean duration of 3rd stage of labour between intraumbilical and intravenous oxytocin,” Journal of Medical and Pharmaceutical Sciences, vol. 12, no. 4, pp. 55–62, 2020.

[33] World Bank, “Nigeria health facility survey guide for data collectors: Measuring structural and process readiness for emergency obstetric care,” World Bank Group Report No. 102437, 2020.

[34] S. Bradley, F. Kamwendo, and E. Chipeta, “Authorization of midwives to perform basic emergency obstetric and newborn care signal functions in Argentina, Ghana, and India: A multi-country validation study,” PLOS ONE, vol. 15, no. 5, Art. no. e0232418, 2020.

[35] E. N. Okeke, I. S. Abubakar, and L. Lawal, “Provision of emergency obstetric care: Midwives' knowledge and involvement in rural health facilities of Cross River State, Nigeria,” African Journal of Midwifery and Women's Health, vol. 16, no. 3, pp. 101–112, 2022.

[36] Federal Ministry of Health and World Health Organization, “Cost-effectiveness and budget impact of introducing heat-stable carbetocin for postpartum hemorrhage prevention in Nigeria,” WHO Country Office Nigeria, 2022.

[37] K. Torpey, C. Anyakora, and A. Bankole, “Oxytocin quality: Evidence to support updated global recommendations on oxytocin for postpartum hemorrhage,” BMC Pregnancy and Childbirth, vol. 20, no. 1, Art. no. 512, 2020.

[38] I. O. O. Abejirinde, R. Douwes, A. Bardají, and T. van den Akker, “Travel of pregnant women in emergency situations to hospital and maternal mortality in Lagos, Nigeria: A retrospective cohort study,” BMJ Global Health, vol. 6, no. 8, Art. no. e005820, 2021. BMJ

[39] A. Banke-Thomas, K. Wright, and S. Kouraogo, “Multistakeholder perspectives on geographical accessibility to emergency obstetric care in Benin City, Nigeria,” BMC Pregnancy and Childbirth, vol. 21, no. 1, Art. no. 412, 2021.

[40] World Health Organization, “WHO recommendation on routes of oxytocin administration for the prevention of postpartum haemorrhage after vaginal birth,” World Health Organization, 2021.

@article{1723745,
      author = {Yusuf Salimat Iyabo (Dr.), Dr. Ogbeye Gbemisola Bolanle},
      title = {Manual Placenta Removal and Umbilical Cord Oxytocin Injection for Postpartum Hemorrhage Management in Nigeria: A Narrative Review of Evidence from 2020 to 2026},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {4},
      pages = {825-837},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1723745.pdf},
      abstract = {Background: Postpartum hemorrhage (PPH) remains the leading cause of maternal mortality in Nigeria, with retained placenta serving as a major contributor to severe obstetric hemorrhage, puerperal sepsis, and emergency surgical interventions. This narrative review synthesizes evidence published between 2020 and 2026 regarding the clinical utility, procedural safety, health systems feasibility, and comparative effectiveness of manual removal of placenta (MRP) and intra-umbilical vein (IUV) oxytocin injection in Nigerian health facilities.
Methods: A comprehensive synthesis was conducted using peer-reviewed journal articles, national clinical guidelines, WHO policy briefs, and implementation study reports published between January 2020 and October 2026. Data were extracted and analyzed across five thematic objectives: epidemiological burden, MRP procedural dynamics, IUV oxytocin effectiveness, health systems readiness, and priority research gaps.

Results: National modeling and facility audits reveal an estimated 28,669 annual PPH deaths in Nigeria, with retained placenta accounting for 0.53% to 1.80% of vaginal deliveries and up to 12.5% of primary PPH cases. Unbooked status (71.4%–88.1%) and grand multiparity are major risk factors. While MRP remains the standard operative intervention for retained placenta, it carries substantial risks of severe hemorrhage, uterine perforation, shock, and puerperal sepsis (12.5%–24.1%), particularly when performed in primary care settings without general anesthesia or parenteral antibiotics. Conversely, IUV oxytocin injection (10–30 IU in 20–30 mL normal saline via the Pipingas technique) delivers concentrated uterotonic therapy directly to the retroplacental bed, significantly shortening third-stage duration and reducing blood loss without invasive uterine instrumentation. However, wide implementation is severely hindered by health system bottlenecks, including a 74% degradation rate of stored oxytocin due to cold-chain failures, acute shortages of long gauntlet gloves, and inadequate emergency transport pathways.

Conclusion: IUV oxytocin represents a highly effective, non-invasive first-line intervention for retained placenta that can minimize emergency MRP transfers and surgical trauma. Integrating IUV oxytocin into Basic Emergency Obstetric and Newborn Care (BEmONC) protocols alongside heat-stable carbetocin scale-up, calibrated drape adoption (E-MOTIVE bundle), and midwife task-sharing is urgently needed to lower maternal mortality in Nigeria.},
      keywords = {Intra-umbilical vein oxytocin, Manual removal of placenta, Nigeria, Postpartum hemorrhage, Retained placenta},
      month = {October},
      doi = {https://doi.org/10.64388/IREV10I4-1723745}
  }